NO953832L - Sykliske forbindelser som kan anvendes som inhibitorer for blodplateglykoprotein IIb/IIIa - Google Patents

Sykliske forbindelser som kan anvendes som inhibitorer for blodplateglykoprotein IIb/IIIa

Info

Publication number
NO953832L
NO953832L NO953832A NO953832A NO953832L NO 953832 L NO953832 L NO 953832L NO 953832 A NO953832 A NO 953832A NO 953832 A NO953832 A NO 953832A NO 953832 L NO953832 L NO 953832L
Authority
NO
Norway
Prior art keywords
cyclic compounds
platelet
glycoprotein iib
iiia
inhibitors
Prior art date
Application number
NO953832A
Other languages
English (en)
Other versions
NO953832D0 (no
Inventor
William Frank Degrado
Sharon Anne Jackson
Shaker Ahmed Mousa
Anju Parthasarathy
Michael Sworin
Maria Rafalski
Original Assignee
Du Pont Merck Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Du Pont Merck Pharma filed Critical Du Pont Merck Pharma
Publication of NO953832D0 publication Critical patent/NO953832D0/no
Publication of NO953832L publication Critical patent/NO953832L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/75—Fibrinogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Denne oppfinnelsen vedrører nye, sykliske forbindelser som inneholder karbosykliske ringsystemer, som kan anvendes som antagonister for blod- plateglykoprotein Ilb/IIIa-komplekset, farmasøytiske preparater som inneholder slike sykliske forbindelser sammen med eller uten andre terapeutiske midler, og fremgangsmåter for anvendelse av disse forbindelsene sammen med eller uten andre terapeutiske midler, for inhiberingen av blodplateaggregasjon, som trombolytika og/eller for behand- ling av andre tromboemboliske sykdom- mer. Denne oppfinnelsen vedrører også fremgangsmåter for anvendelse av de sykliske forbindelsene ifølge oppfin- nelsen i kombinasjon med antikoagula- sjonsmidler, slik som warfarin eller heparin, eller ytterligere anti- blodplatemidler, slik som aspirin, piroxicam eller ticlopidin, eller trom- bininhibitorer, slik som borpeptider, hirudin eller argatroban, eller trom- bolytiske midler, slik som vevsplas- minogenaktivator, anistreplase, urokin- ase eller streptokinase, eller kombina- sjoner derav, til behandlingen av trom- boemboliske sykdommer.
NO953832A 1993-03-29 1995-09-28 Sykliske forbindelser som kan anvendes som inhibitorer for blodplateglykoprotein IIb/IIIa NO953832L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3844893A 1993-03-29 1993-03-29
PCT/US1994/003223 WO1994022910A1 (en) 1993-03-29 1994-03-28 CYCLIC COMPOUNDS USEFUL AS INHIBITORS OF PLATELET GLYCOPROTEIN IIb/IIIa

Publications (2)

Publication Number Publication Date
NO953832D0 NO953832D0 (no) 1995-09-28
NO953832L true NO953832L (no) 1995-11-28

Family

ID=21900014

Family Applications (1)

Application Number Title Priority Date Filing Date
NO953832A NO953832L (no) 1993-03-29 1995-09-28 Sykliske forbindelser som kan anvendes som inhibitorer for blodplateglykoprotein IIb/IIIa

Country Status (10)

Country Link
EP (1) EP0691987A1 (no)
JP (1) JPH08508498A (no)
AU (1) AU6415894A (no)
CA (1) CA2159070A1 (no)
FI (1) FI954556A0 (no)
HU (1) HUT72896A (no)
NO (1) NO953832L (no)
NZ (1) NZ263456A (no)
PL (1) PL310896A1 (no)
WO (1) WO1994022910A1 (no)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08509708A (ja) * 1993-03-29 1996-10-15 ザ・デュポン・メルク・ファーマシュウティカル・カンパニー 血小板糖蛋白▲ＩＩ▼ｂ／▲ＩＩＩ▼ａ抑制剤の調製のための新規な方法および中間体化合物
US5879657A (en) * 1993-03-30 1999-03-09 The Dupont Merck Pharmaceutical Company Radiolabeled platelet GPIIb/IIIa receptor antagonists as imaging agents for the diagnosis of thromboembolic disorders
KR100512671B1 (ko) * 1996-11-27 2005-09-07 아벤티스 파마슈티칼스 인크. 항 Ｘａ 활성을 지닌 화합물 및 혈소판 응집 길항제 화합물을포함하는 약제학적 조성물
US6010911A (en) * 1997-04-30 2000-01-04 Medtronic, Inc. Apparatus for performing a heparin-independent high sensitivity platelet function evaluation technique
US6537520B1 (en) 1998-03-31 2003-03-25 Bristol-Myers Squibb Pharma Company Pharmaceuticals for the imaging of angiogenic disorders
GB0623607D0 (en) 2006-11-27 2007-01-03 Haemostatix Ltd Tissue adhesive
CA2677045C (en) 2007-01-31 2016-10-18 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
AU2008232709C1 (en) 2007-03-28 2015-01-15 President And Fellows Of Harvard College Stitched polypeptides
US11673914B2 (en) 2009-11-10 2023-06-13 Allegro Pharmaceuticals, LLC Peptide therapies for reduction of macular thickening
ES2730927T3 (es) 2009-11-10 2019-11-13 Allegro Pharmaceuticals Llc Composiciones y métodos para inhibir la adhesión celular o dirigir agentes diagnósticos o terapéuticos a sitios de unión a RGD
SI2603600T1 (sl) 2010-08-13 2019-04-30 Aileron Therapeutics, Inc. Peptidomimetični makrocikli
JP6106159B2 (ja) 2011-05-09 2017-03-29 アレグロ ファーマシューティカルズ インコーポレイテッドＡｌｌｅｇｒｏ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． Ｒ−ｇ−システイン酸ペプチドを含む医薬組成物
TWI643868B (zh) 2011-10-18 2018-12-11 艾利倫治療公司 擬肽巨環化合物
US8987414B2 (en) 2012-02-15 2015-03-24 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
KR102112373B1 (ko) 2012-02-15 2020-05-18 에일러론 테라퓨틱스 인코포레이티드 펩티드모방체 마크로사이클
AU2013337388B2 (en) 2012-11-01 2018-08-02 Aileron Therapeutics, Inc. Disubstituted amino acids and methods of preparation and use thereof
AU2015320545C1 (en) 2014-09-24 2020-05-14 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and formulations thereof
WO2016049359A1 (en) 2014-09-24 2016-03-31 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
MX2017011834A (es) 2015-03-20 2018-04-11 Aileron Therapeutics Inc Macrociclos peptidomimeticos y usos de los mismos.
JP2018528217A (ja) 2015-09-10 2018-09-27 エルロン・セラピューティクス・インコーポレイテッドＡｉｌｅｒｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． Ｍｃｌ−１のモジュレーターとしてのペプチド模倣大環状分子

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2636066B1 (fr) * 1988-09-02 1991-10-25 Centre Nat Rech Scient Derives de cyclopeptides, utilisables comme inhibiteurs selectifs vis-a-vis de proteases a serine active
US5384309A (en) * 1989-07-17 1995-01-24 Genentech, Inc. Cyclized peptides and their use as platelet aggregation inhibitors
AU6470590A (en) * 1989-10-23 1991-04-26 Smithkline Beecham Corporation Cyclic anti-aggregatory peptides
IL103252A (en) * 1991-09-30 1997-03-18 Du Pont Merck Pharma CYCLIC COMPOUNDS USEFUL AS INHIBITORS OF PLATELET GLYCOPROTEIN IIb/IIIa AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

Also Published As

Publication number Publication date
JPH08508498A (ja) 1996-09-10
PL310896A1 (en) 1996-01-08
FI954556A (fi) 1995-09-26
EP0691987A1 (en) 1996-01-17
FI954556A0 (fi) 1995-09-26
CA2159070A1 (en) 1994-10-13
HU9502832D0 (en) 1995-11-28
WO1994022910A1 (en) 1994-10-13
HUT72896A (en) 1996-06-28
AU6415894A (en) 1994-10-24
NZ263456A (en) 1996-11-26
NO953832D0 (no) 1995-09-28

Similar Documents

Publication Publication Date Title
NO953832L (no) Sykliske forbindelser som kan anvendes som inhibitorer for blodplateglykoprotein IIb/IIIa
Takatsuka et al. Molecular characterization of L-amino acid oxidase from Agkistrodon halys blomhoffii with special reference to platelet aggregation
DK36991A (da) Vaevsplasminoaktivator-(t-pa)-variant med zymogene eller fibrinspecifikke eller plasmakoagel-specifikke egenskaber, fremgangsmaade til fremstilling deraf, dna-sekvens, som koder for varianten, replicerbar udtrykkelsesvektor for denne og vaertsceller transformeret med vektoren
DK0730590T3 (da) Isoxazolin og isozazol fibrinogenreceptorantagonister
Marshall et al. Coagulant and anticoagulant actions of Australian snake venoms
Salazar et al. Hemostatic and toxinological diversities in venom of Micrurus tener tener, Micrurus fulvius fulvius and Micrurus isozonus coral snakes
Suntravat et al. cDNA cloning of a snake venom metalloproteinase from the eastern diamondback rattlesnake (Crotalus adamanteus), and the expression of its disintegrin domain with anti-platelet effects
Collen Thrombolytic therapy
DE69411584D1 (de) Isoxazoline derivate anwendbar als fibrinogen rezeptor antagonisten
Komiyama et al. Protection from anthrax toxin-mediated killing of macrophages by the combined effects of furin inhibitors and chloroquine
NO941561L (no) Bifunksjonelle urokinasevarianter med forbedrede fibrinolytiske egenskaper og trombinhemmende virkning
ES2337879T3 (es) Procedimiento de dosificacion de la fibrina soluble.
Furukawa et al. Factor X converting and thrombin-like activities of Bothrops jararaca snake venom
BRPI0409557A (pt) proteìna inibidora recombinante de calicreìna, seqüência de dna, vetor de expressão, célula hospedeira, composição farmacêutica e seu uso, método de produção de proteìna inibidora recombinante de calicreìna e kit de diagnóstico para detecção de calicreìna
Amel et al. Purification and characterization of a new serine protease (VLCII) isolated from Vipera lebetina venom: Its role in hemostasis
Markland et al. Applications of snake toxins in biomedicine
Bang Leeches, snakes, ticks, and vampire bats in today's cardiovascular drug development.
Moukhametova et al. Properties of the urokinase-type plasminogen activator modified with phenylglyoxal
South et al. Conformational quiescence of ADAMTS‐13 prevents proteolytic promiscuity: reply
Matsushima et al. Activation of fibrinolysis with the protease from Dermatophagoides farinae
Islam et al. Longistatin, a novel plasminogen activator from vector ticks, is resistant to plasminogen activator inhibitor-1
Schreuder et al. Minimally modified human blood coagulation factor X to bypass direct factor Xa inhibitors
Takada et al. Release of Bβ peptides from fibrinogen or fibrin in the presence of α2antiplasmin
DK104390D0 (da) Vaevs-plasminogen aktivatorforbindelse, dna, der koder herfor, udtrykkelsesvektor indeholdende dette dna, vaertsceller transformeret med udtrykkelsesvektoren, fremgangsmaade til fremstilling af aktivatoren og farmaceutisk praeparat indeholdende denne
TAKADA et al. Studies on interactions of α2 plasmin inhibitor with plasmin